Exenatide
ECHO
AstraZeneca · Phase 3 · Completed · Enrollment 42
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Exenatide once weekly extended-release | 6 participants | 4 participants | 7 participants | n/r | 0 |
| Matching placebo | 3 participants | 4 participants | 3 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.